Tags : Daiichi Sankyo

PharmaShots Weekly Snapshot (Oct 19 – 23, 2020)

Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week Published: Oct 23, 2020 | Tags: Akebia, Results, Vadadustat, P-lll, INNO2VATE Global Study, Anemia, Chronic Kidney Disease Sanifit Presents Results of SNF472 for the Treatment of Vascular Calcification at ASN Kidney Week 2020 Published: Oct 22, 2020 […]Read More

Daiichi Sankyo Signs a Research Agreement Gustave Roussy for DS-1062

Shots: Gustave Roussy to receive funding and support from Daiichi Sankyo for integrative research program including clinical, translational, and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer respectively The research program includes two P-II studies evaluating the efficacy, safety, and markers of response and resistance to DS-1062 & patritumab deruxtecan in […]Read More

Daiichi Sankyo in Talks with AstraZeneca for the Supply of

Shots: Following the AstraZeneca’s discussion with the Japanese government to introduce COVID-19 vaccine in Japan, Daiichi Sankyo has advanced its conversation with AstraZeneca to formulate the vaccine, including vial filling, packaging, and storage Daiichi Sankyo plans to receive Oxford’s undiluted vaccine, which it will finish at its own facilities. The collaboration allows AstraZeneca to reach […]Read More

AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki)

Shots: The two companies divulged the results of ongoing P-II DESTINY-CRC01 study assessing Enhertu in patients with HER2+ unresectable and/or m-colorectal cancer, prior treated with 2L standard therapies. Results: ORR (45.3%); DCR (83.0%); PFS (6.9mos.); subgroup patients including patients with treated with a prior anti-HER2 regimen, ORR (43.8%) with a median treatment duration of 4.8mos. […]Read More

PharmaShots Weekly Snapshot (May 18-22, 2020)

1. BMS Reports EMA’s Validation of MAA for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486 Published: May 22, 2020 | Tags: bb2121, BMS ,CC-486, EMA, ide-cel Idecabtagene, Vicleucel MAA 2. Gilead Plans to Submit MAA to CDSCO for its Remdesivir to Treat COVID-19 in India Published: May 21, 2020 | Tags: Gilead, Plans, Submit, MAA, CDSCO, Remdesivir, COVID-19, […]Read More

PharmaShots Weekly Snapshot (March 30 – April 03, 2020)

1. Sorrento Initiates the Next Phase of its Collaboration with Celularity Published: Apr 02, 2020 | Tags: Sorrento, Initiates, Next Phase, Collaboration, Celularity 2.  Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic Published: Apr 03, 2020 | Tags: Celltrion, Enters, Next Phase, Development, Antiviral Therapy, Combat, COVID-19 Pandemic 3. […]Read More

Daiichi Sankyo Signs a Non-Exclusive License Agreement with Ultragenyx for

Shots: Ultragenyx to receive $200m up front including $125M in cash & $75M equity investment at $60/share, $25M on completion of technology transfer the HeLa PCL and HEK293 platforms along with royalties on sales of products manufactured in either system Ultragenyx get a non-exclusive license to IP, including know-how and patent applications, regarding its manufacturing […]Read More